Revance Therapeutics Inc (RVNC)

[DewDiligence]

There are no pricing considerations in that sticky (#msg-123290722). Do we know if at least the cost expected to manufacture the product is similar to that of Botox?

Manufacturing cost is a very low (<10%) proportion of the price of Botox and other commercial botulinum toxins, so whatever difference there might be between RT002 and Botox in manufacturing cost is immaterial in the overall scheme of things.

On pricing, I expect RT002 to sell at a par with Botox if RT002 ends up getting a label with a slightly longer duration of action than Botox in certain indications. If RT002’s label is essentially the same as Botox’s with respect to duration of action, I expect RT002 will sell at a 10-15% discount to Botox in order to counter Botox’s strong brand awareness.

Good questions, by the way.